cyrilzakka/clinical-trials huggingface dataset:
Lymph Node Mapping in Finding Metastatic Disease in Patients with Sebaceous Gland Cancer of the Eyelid

This phase II trial studies how well lymph node mapping works in finding disease that has spread from the place where it started to other places in the body in patients with sebaceous gland cancer of the eyelid. Lymph node mapping may help in planning surgery to remove cancer and affected lymph nodes.

PRIMARY OBJECTIVES:

I. Identify the rate of SLN (sentinel lymph node) positivity for eyelid sebaceous gland carcinomas.

II. Identify the false negative events associated with SLN biopsy for sebaceous gland carcinomas.

SECONDARY OBJECTIVE:

I. Record any side effects associated with SLN biopsy for sebaceous gland carcinoma of the eyelid.

OUTLINE:

Patients receive technetium Tc 99m sulfur colloid intradermally (ID) and then undergo lymph node mapping and SLN biopsy.

After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 4 years.

Eligibility Criteria:
Inclusion Criteria:

* Possible or suspicious sebaceous gland carcinoma of the eyelid
* A CXR (chest x-ray), liver enzymes, and a head and neck computed tomography (CT), a single photon emission computed tomography (SPECT/CT) or magnetic resonance imaging (MRI) and an ultrasound negative for clinical evidence of metastasis
* Patient provided written informed consent; in the event that non-English speaking participants are eligible for this study, a short form (if applicable) or an informed consent document (ICD) in their language, will be utilized and completed in accordance with the M.D. Anderson Cancer Center (MDACC) Policy for Consenting Non-English Speaking Participants

Exclusion Criteria:

* Pregnant or nursing females
Effect of Music on Burden of Dental Implant Surgery

Personnalized music can decrease the burden of care.

This experimental clinical trial examines the effect of personalized musical intervention on the burden of dental implant surgery. The intervention consists of a personnalized musical intervention and the control group consists of audio books. The burden of dental implant surgery will be defined by a composite variable including surgical pain, state anxiety and dissatisfaction with dental implant surgery.


Eligibility Criteria:
Inclusion Criteria:

Patients included in the study:

* will have an adequate understanding of the French or English language both written and spoken,
* will have the physical and psychological ability to understand and complete the questionnaires used in the study,
* will consent to follow research instructions,
* will consent to follow the allocated sequence of interventions without prior notification,
* will undergo a dental implant surgery not exceeding 2 hours,

Exclusion Criteria:

Patients :

* do not have the necessary clinical criteria to receive implants.
* have an implant surgical treatment that would increase treatment time beyond 2 hours,
* have a history of neurological disorders, diagnosed with severe psychiatric disorders (e.g. schizophrenia, bipolar disorder), substance abuse
* have a major diagnosed hearing problem.
Incidence of Regurgitation in Patients Undergoing Intubation in Semi-fowler v/s Supine Position

One of the most dreaded complication of general anaesthesia is aspiration of gastric contents after induction of general anaesthesia.Many endeavours and measures have been practiced to reduce the incidence of aspiration pneumonia.One such method is to intubate the patient in semi-fowler or supine posture.My study is aimed to find out safe and best position between these two after induction of general anaesthesia to prevent aspiration pneumonia.


Eligibility Criteria:
Inclusion Criteria:

* Adults 18-60 years of age
* Must be able to talk

Exclusion Criteria:

* patients less than 18 years of age or above 60,
* Pregnant women
* Handicapped individuals
* patients with intestinal obstruction
Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy

This observational study is designed to evaluate the reported outcomes for patients receiving topical therapy for the treatment of pain, fungal infections or skin scars. The patients will complete the Patient Reported Outcome (PRO) survey monthly and provide valuable data on the patients perception of their health status and well being while receiving therapy.

This observational study is designed to evaluate the reported outcomes for patients receiving topical therapy for the treatment of pain, fungal infections or skin scars. The patients will complete the Patient Reported Outcome (PRO) survey monthly and provide valuable data on the patients perception of their health status and well being while receiving therapy.

Patients are enrolled for 18 months. The investigator will complete a global patient assessment monthly of the patient's condition.

Eligibility Criteria:
Inclusion Criteria:

1. An 18 to 85 years old (inclusive) female or male patient
2. Prescribed compound for the treatment of pain, wound healing or surface skin scar by their Principal Investigator
3. Any systemic disease (cardiac, renal, or hepatic) must be well controlled.
4. Has no skin lesions at the site of application of study medication except for wound under treatment
5. Able to provide informed consent

Exclusion Criteria:

1. Pregnant or lactating females or women at the child bearing potential not using effective contraception.
2. Use of other topical or transdermal medication. Patients may be withdrawn for a period of 2 weeks from all topical or transdermal medications prior to study initiation.
3. Hypersensitivity to local anesthetic or other ingredients of the compounded creams to be used in a study.
4. Prior reconstruction skin surgery or skin grafts in the area of cream application preventing absorption of cream except for the treatment of surface skin scar
5. Chronic pain conditions not expected to respond to topical pain medication such as deep abdominal pain, or from conditions such as cancer, or gouty arthritis.
Cornual Wedge Resection Outcome

Cornual pregnancy is a rare form of ectopic pregnancy that accounts for 2% to 4% of ectopic pregnancies, with a mortality rate between 2.0% and 2.5%. Traditionally, interstitial pregnancies were treated by laparotomy with cornial resection or hysterectomy. However, nowadays, increasingly interstitial pregnancies are treated by laparoscopic cranial resection.

Although this technique can potentially protect the fertility of the patient, it carries a serious risk of bleeding and requires a surgical experience.


Eligibility Criteria:
Inclusion Criteria:

* cornual ectopic pregnancy
* Patients undergoing laparoscopic cornual wedge resection

Exclusion Criteria:

* medical treatment area due to cornual pregnancy
* laparotomy
* conservatively managed patients
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance

Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance

The aim of the study is to evaluate the safety, efficacy, patient comfort, and patient satisfaction after Evoke treatment

Eligibility Criteria:
Inclusion Criteria:

* - Signed informed consent to participate in the study.
* Female and male subjects, 35 and 75 years of age at the time of enrolment
* If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
* In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
* General good health confirmed by medical history and skin examination of the treated area.
* Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
* The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period.

Exclusion Criteria:

* - Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
* Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance, unless deep enough in the periostal plane.
* Current or history of skin cancer, or current condition of any other type of cancer, or premalignant moles.
* Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
* Pregnancy and nursing.
* Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
* Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
* Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.
* Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
* History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
* History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
* Any surgery in treated area within 3 months prior to treatment.
* Six months delay is required if other recent treatments like light, CO2 laser or RF were performed on the same area.
* Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
* As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient
Bonefos and the Consumption of Analgesics

The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.


Eligibility Criteria:
Inclusion Criteria:

* Breast cancer or prostate cancer or multiple myeloma.
* Bone metastasis.
* Ability to use analgesics and clodronate 1600 mg/day.

Exclusion Criteria:

* Hypersensitivity to bisphosphonates.
* Clodronate in previous therapy.
* Concomitant use of other bisphosphonates.
* Serious renal insufficiency.
The Significance of Postoperative Muscle Wasting in Pancreatic Cancer

To assess the impact of preoperative sarcopenia and postoperative skeletal muscle wasting on the outcomes of patients with resectable pancreatic cancer who underwent pancreatectomy.

Previous studies have revealed that sarcopenia, defined as generalized loss of skeletal muscle mass, is a poor prognostic factor following surgery. However, research focusing on postoperative muscle wasting and its influence on the prognosis of resectable pancreatic cancer (PC) is limited. Investigators retrospectively reviewed 208 patients who underwent pancreatectomy for PC at the National Cheng Kung University Hospital (NCKUH) between June 2002 and April 2020. Clinical information regarding patient characteristics, pathological parameters, and biochemical features was collected from all patients using electronic medical records (EMRs) under an IRB-approved protocol (B-ER-110-420) at NCKUH. Preoperative psoas major area and the degree of muscle reduction at 3 months postoperatively were calculated using computed tomography to define sarcopenia and drastic muscle wasting. Patients were assigned to two groups based on sarcopenia or drastic muscle wasting, and compared for postoperative morbidity, disease free survival (DFS), and overall survival (OS).

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of pancreatic cancer
* Must be able to undergo pancreatectomy
* Must be able to undergo pre- and post-operative abdominal computed tomography scan

Exclusion Criteria:

* Unresectable pancreatic cancer
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

This trial will evaluate the efficacy and safety of pemetrexed and bevacizumab combination in patients with pretreated, advanced non small cell lung cancer (NSCLC).

Pemetrexed is and an effective and well tolerated cytotoxic agent in the 2nd line treatment of advanced or metastatic non small cell lung cancer (NSCLC). Recently, a phase III study of 1st line treatment in patients with advanced or metastatic NSCLC showed that the addition of bevacizumab to a platinum-based regimen provided a survival benefit. There are patients with NSCLC who have not received bevacizumab and have relapsed after 1st and/or 2nd line therapy. The evaluation of bevacizumab plus chemotherapy in such patients is justified. This study will evaluate the combination of pemetrexed and bevacizumab as 2nd or 3rd line treatment of NSCLC.

Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically confirmed,
* Unresectable locally advanced (stage IIIB) or metastatic (stage IV) non-squamous NSCLC
* At least one and no more than two previous chemotherapy regimens for advanced - or metastatic NSCLC
* Measurable disease, defined as at least 1 bidimensionally measurable lesion ≥ 20 X 10 mm.
* Age ≥ 18 years.
* Performance status (WHO) 0-2.
* Life expectancy of at least 12 weeks.
* Adequate bone marrow (ANC ≥ 1,500/mm3, PLT ≥ 100,000/mm3, Hgb ≥ 11 g/dL), liver (Bilirubin ≤ 1.5 Upper normal limit, SGOT/SGPT ≤ 2.5 Upper normal limit in the absence of liver metastases or ≤ 5 Upper normal limit in the presence of liver metastases), and renal function (Creatinine ≤ 1,5 Upper normal limit).
* Patients must be able to understand the nature of this study and give written informed consent

Exclusion Criteria:

* Previous therapy with pemetrexed
* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
* Pregnant or lactating women
* Any serious, uncontrolled comorbidity on the investigator's judgment. Uncontrolled infection
* Any sustained chronic toxicity \> grade 2 according to the NCI CTCAE (version 3.0)
* Symptomatic neuropathy \> grade 2 according to the NCI CTCAE (version 3.0)
* Brain metastases, except if radiated and asymptomatic
* Radiotherapy within the previous 4 weeks
* Previous radiotherapy to the only measurable lesion
* Proteinuria ≥ 500 mgr of protein daily
* Hemoptysis \> 10 cc per event
* Clinically significant hematemesis
* Centrally located lesion or in contact with major vessels
* Pulmonary lesion with cavitation
* Documented hemorrhagic diathesis or coagulation disorder
* Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, unstable angina, LVEF \< normal, ventricular arrhythmia, uncontrolled hypertension)
* Thrombotic event within the previous 6 months
* Concurrent use of aspirin \> 325 mgr daily, low molecular weight heparin in therapeutic dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents
* Concurrent treatment with other anti-cancer drug
* Major surgical procedure within the previous 4 weeks
Socially Isolated Older Adults Living With Dementia

The lack of efficacious research-based interventions for sexual and gender minority (SGM) older adults living with Alzheimer's disease and other dementias, combined with the heightened risk of cognitive impairment in this population, presents a significant public health problem. SGM older adults are at elevated risk of social isolation and experience significant barriers to healthcare access. Existing interventions for older adults with dementia have been found to be effective for caregiving dyads. Yet SGM older adults, compared to heterosexuals, are significantly less likely to be married or to have biological family members to support them. A significant proportion of SGM older adults living with dementia have no caregiver or care network. The goal of the proposed research is to design and pilot test the cultural appropriateness, acceptability, and feasibility of an innovative translation of a personalized care network-RDAD (Reducing Disability in Alzheimer's Disease) to support those living with dementia without a family caregiver, directly addressing unique SGM-specific risk factors.

We will address the following aims:

Aim 1. Develop a personalized care network-RDAD intervention suitable for SGM older adults living with dementia without caregivers.

Aim 2. Implement a preliminary randomized controlled trial (RCT) of 30 participants with 2 arms (routine medical care vs. the personalized care network-RDAD approach) to assess the acceptability, feasibility, and initial efficacy of the intervention.

Eligibility Criteria:
Inclusion Criteria:

* Age at enrollment is 50 years of age or older
* Self-identify as LGBT (or sexual or gender non-binary or same sex sexual behavior)
* Have early stage dementia, including Alzheimer's disease or needs help with complex daily activities
* Living in the community, not in a care facility.

Exclusion Criteria:

* Known terminal illness (with death anticipated within the next 12 months)
* Hospitalization for a psychiatric disorder in the 12 months prior to baseline
* Have more than early stage dementia
* Any physical limitations/chronic conditions preventing participation in an exercise program.
I-STAND R21: Reducing Sedentary Time in Older Adults

The investigators are doing a study to learn how to support patients aged 60+ in taking more breaks from sitting and reducing total sitting time. The goal of the study is to find out if a sitting time reduction intervention reduces sitting time compared with a control group.

More than one-third of American adults over 60 have a body mass index \> 30 kg/m2. These older adults have more sedentary time than any other group -- an average of 10-11 hours per day. Reducing the sedentary behavior of older adults with obesity, rather than only promoting more intensive physical activity, could provide a more feasible approach to health promotion.

This randomized control pilot trial will evaluate a 12-week intervention to decrease sitting time and increase standing time and light physical activity among sedentary older adults a body mass index \> 30 kg/m2 as compared to control group. Baseline and 12-week measurements include anthropometric measures, blood draw by finger stick, cardiovascular health assessments, physical function tasks, and a survey. The intervention will consist of two in-person visits with a health coach followed by phone-based coaching.

Eligibility Criteria:
Inclusion Criteria:

* Kaiser Permanente Washington enrollees
* Men and women
* Age 60 - 89
* BMI 30 - 50 (calculated based on most recent height ever and most recent weight taken within previous 18 months)
* Primary care within Integrated Group Practice
* Continuously enrolled at Kaiser Permanente Washington for previous 12 months
* No record of death
* Not on the No Contact list
* Speaks and writes English
* Able to hold a conversation by phone (no hearing or other limitations)
* Self-reported sitting time of 6 hours/day or more
* Self-reported ability to stand with or without an assistive device
* Self-reported ability to walk one block with or without an assistive device
* Available for the study duration
* Able to come to Kaiser Permanente Washington Health Research Institute's research clinic for measurement visits
* Willing to wear study activity monitors

Exclusion Criteria:

* Resides in long-term care, hospice care, or skilled nursing facility (previous 12 months)
* Wheelchair bound
* Diagnosis of dementia, serious mental health disorder, or substance use disorder (previous 24 months)
* Use of an assistive device
Evaluation of GeneXpert HIV-1 as The Gold Standard Test for HIV-1 Viral Load Count

This is a cohort study on HIV-1 patients treated in outpatient and inpatient wards of Tangerang District Hospital. The participant will be interviewed and retrieved for their demographics, treatment history, CD4 and viral load history. Blood will be drawn for HIV-1 viral load examination using Xpert® HIV-1 Viral Load \[Cepheid\], in-house qRT-PCR, and REALTIME HIV-1 VIRAL LOAD \[Abbott\]

Participant candidate will be screened at Tangerang District Hospital's outpatient and inpatient units. The purpose is to get various VL values from participants with various clinical conditions (light-heavy). If a participant is willing to participate and has signed the Informed Consent Form (ICF), he/she will be interviewed for demographic data and case history (age, gender, first HIV diagnosis). After that, the participant will be physically examined (height, weight, and vital signs). Other information, such as current HIV clinical stage, current ART regimen, Viral Load value (final and highest), and CD4 (final and lowest) are collected from participant's medical records.

The participant's blood will be drawn as much as 9 ml and will be processed to obtain plasma. Plasma will be aliquoted into 3 vials for VL test using 3 devices: 1 ml using Xpert HIV-1, 1 ml using PCR (Abbott) at Dharmais Hospital, and 1 ml or leftover plasma using PCR (ABI7500) at INA-RESPOND's reference laboratory. The process follows the manufacturer's manual or the standard of sample preparation procedure and the operation of the devices at each hospital.

The result of viral load measurement will be informed to the participant via the attending physician during the participant's routine HIV treatment visit to the hospital.

Eligibility Criteria:
Inclusion Criteria:

* HIV positive patient by the HIV Diagnoses Guideline in the Tangerang District Hospital.
* Patient older than 18 years and above.
* Willing and signed the informed consent (ICF).
* Willing to comply with the study procedures.

Exclusion Criteria:

* Suffered from a disease or having condition that could complicated the blood drawing process or increasing the risk of disease complications.
* Currently imprisoned.